ERBB2 and gastric adenocarcinoma: According to the NCCN Guidelines Version 2.2018, HER-2 gene and programmed death-ligand 1 (PD-L1) testing at the time of diagnosis are recommended for all advanced gastric adenocarcinoma patients if metastatic disease is documented or suspected.